Immunoglobulin News and Research

RSS

Impact of type I interferon (IFN) autoantibodies in critical COVID-19

A new preprint discusses the pathogenesis of this critical COVID-19 with reference to autoimmune phenomena involving the key antiviral type I interferon pathway.

12 Mar 2021

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19).

11 Mar 2021

People previously infected with SARS-CoV-2 may achieve immunity after one mRNA vaccine dose, finds study

A team of researchers led by Thomas W. McDade of Northwestern University suggests people who were previously infected with SARS-CoV-2, the causative agent of COVID-19, may require only one dose of the mRNA vaccine to obtain immunity.

11 Mar 2021

Researchers develop assay for qualitative assessment of SARS-CoV-2 neutralizing antibodies

To address the need for a high-quality neutralization assay against SARS-CoV-2, researchers from the NIAID modified and optimized a previously established fluorescence reduction neutralization assay (FRNA) to provide a quantitative assessment of a large number of infected cells through the use of a high-content imaging system.

11 Mar 2021

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Researchers from Germany and the US investigated the efficacy of neutralizing antibodies against newer variants using serum and saliva samples obtained from groups of infected, vaccinated (with Pfizer BNT-162b2), and uninfected individuals. The researchers started this study to uncover vaccine-induced immune response and show the efficiency of antibody binding and neutralization in SARS-CoV-2 variants.

10 Mar 2021

Researchers characterize antibody responses to COVID-19 mRNA-based vaccine

A team of scientists from the USA and Canada has recently characterized the antibodies developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in response to an mRNA-based coronavirus disease 2019 (COVID-19) vaccine.

10 Mar 2021

Pfizer COVID-19 vaccine elicits antibodies in blood and breastmilk simultaneously, finds study

A new study adds to the sum of knowledge around this issue, showing a highly synchronized and rapid development of an antibody response in breast milk and serum, which reached stable levels around two weeks after the second dose of the vaccine was administered.

10 Mar 2021

Study reveals novel approach to reduce the risk of thrombosis by using IgM antibodies

Thrombotic occlusion of blood vessels, which leads to myocardial infarctions, strokes and venous thromboembolisms, is the major cause of death in the western hemisphere.

9 Mar 2021

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers at the Pitié Salpêtrière Hospital, Department of Virology, Paris, France determined that in BNT162b2-vaccinated participants who received two doses, their sera harbored at least a neutralizing titer against the three SARS-CoV-2 variants.

8 Mar 2021

Researchers identify new molecular mechanisms in chronic skin inflammation

Frequently occurring chronic skin inflammation like in atopic dermatitis (AD or neurodermatitis) and psoriasis have different causes such as genetic predisposition, stress or allergens.

5 Mar 2021

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

A new study details the results from a single dose of the FINLAY FR 1A recombinant dimeric receptor-binding domain (RBD) base vaccine during a phase I clinical trial with 30 COVID-19 convalescents to test its capacity for boosting natural immunity.

5 Mar 2021

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

Scientists have recently developed a novel alternative molecular display technology called Molecular Indexing of Proteins by Self Assembly (MIPSA). Their research explains how this technology overcomes the critical disadvantages of PLATO and other full-length protein array technologies.

5 Mar 2021

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

A new study reports positive outcomes from two new vaccine candidates. The research, led by Axel T. Lehrer from the University of Hawaii at Manoa, studied mice's immune response when administered the CoVaccine HT adjuvant with an insect-cell expressed SARS-CoV-2 spike protein ectodomain.

4 Mar 2021

Novel host-viral-microbiome interactions during COVID-19 may determine outcome

A new preprint on the medRxiv* server discusses how the underlying disease mechanisms are regulated such that the local or mucosal immune response is distinct from the systemic response.

4 Mar 2021

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.

3 Mar 2021

Pfizer SARS-CoV-2 vaccine effective from day 11 post 1st vaccination

New research from a team of scientists in Australia finds that the second ‘booster’ dose of the Pfizer-BioNTech vaccine did not increase vaccine efficacy against severe acute respiratory syndrome (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). The results suggest one dose of the vaccine was sufficient in providing a robust immune response 11 days after inoculation.

3 Mar 2021

Survey reveals impact of Pfizer-BioNTech vaccination in the UK

Researchers at Imperial College London in the UK have reported on round five of the REal-time Assessment of Community Transmission-2 (REACT-2) program – a cross-sectional community survey measuring the prevalence of antibodies against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among adults in England.

2 Mar 2021

Immunoglobulin News and Research

Impact of type I interferon (IFN) autoantibodies in critical COVID-19

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

People previously infected with SARS-CoV-2 may achieve immunity after one mRNA vaccine dose, finds study

Researchers develop assay for qualitative assessment of SARS-CoV-2 neutralizing antibodies

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Researchers characterize antibody responses to COVID-19 mRNA-based vaccine

Pfizer COVID-19 vaccine elicits antibodies in blood and breastmilk simultaneously, finds study

Study reveals novel approach to reduce the risk of thrombosis by using IgM antibodies

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers identify new molecular mechanisms in chronic skin inflammation

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

Novel host-viral-microbiome interactions during COVID-19 may determine outcome

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Pfizer SARS-CoV-2 vaccine effective from day 11 post 1st vaccination

Survey reveals impact of Pfizer-BioNTech vaccination in the UK

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

Study demonstrates the novel agonistic effect of curcumin on lipid transcription

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News